Notably, we find that TGF-β inhibitor LY 2157299 is a potential therapeutic to decrease metastasis without exacerbating sepsis in the setting of liver and peritoneal metastasis nude mice with AIC-induced NETs, which raise the possibility to prolong the survival of GC patients. Here, TGFB1 is linked to gastric cancer.